Drug Discovery Stories, Volume Two showcases the discovery journeys of recent blockbuster drugs approved between 2023 and 2024, along with promising drug candidates. This book delves into structural biology, biological functions of targets, hit compound identification, hit-to-lead optimization, binding modes, key biological and pharmacokinetic data, and clinical results. It also covers other candidate compounds against the same targets and includes additional content based on the authors' choices. The series addresses the rapid evolution in drug discovery and development, appealing to those in chemical biology, synthetic chemistry, and pharmacology.By highlighting interdisciplinary collaboration, the authors plan to release updated editions every few years to ensure the content reflects the latest achievements and breakthroughs in the field.
- Analyzes the drug discovery stories of different blockbuster drugs
- Covers key aspects related to the drug development of the drugs
- Includes the newly approved drugs
Sprache
Verlagsort
Dateigröße
ISBN-13
978-0-443-33886-1 (9780443338861)
Schweitzer Klassifikation
1. Daprodustat (GSK-1278863): A Small Molecule Hypoxia Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor for Anemia2. Repotrectinib (TPX-0005): a macrocyclic ALK/ROS1/TRK inhibitor for the treatment of non-small cell lung cancer3. FRUZAQLA (fruquintinib): a selective oral inhibitor of VEGFR -1, -2 and -3 for treating for adults with metastatic colorectal cancer4. Ensitrelvir: an orally active 3C-like protease inhibitor for COVID-19.5. Danuglipron: Pioneering Oral GLP1 Receptor Agonists Paving the Way for Revolutionizing Diabetes Treatment6. Remdesivir: An Early Repurposed RNA-Dependent RNA Polymerase Inhibitor for Treating COVID-197. RNK05047: A chaperone-mediated protein degrader that selectively targets BRD4 while recruiting the HSP90 chaperone8. Risdiplam: an Orally Active Survival Motor Neuron (SMN2) pre-mRNA Splicing Modifier for Spinal Muscular Atrophy (SMA) in pediatric and adult patients9. Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-ß-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections10. Etrasimod: a selective sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis11. NX-5948: an BTK degrader in Ph. Ia/Ib for patients with advanced B-cell malignancies12. Omaveloxolone (RTA-408): an NRF2 activator for Friedreich's ataxia13. Azvudine: a reverse transcriptase inhibitor for AIDS and COVID-19 treatment14. Leniolisib: a potent and selective PI3Kd inhibitor for treating activated PI3Kd syndrome15. Leritrelvir (RAY1216): a novel a-ketoamide based peptidomimetic inhibitor of SARS-CoV-2 main protease for COVID-19 treatment16. Belzutifan: a first-in-class oral HIF-2a inhibitor approved for patients with Von Hippel-Landau (VHL) disease-associated renal cell carcinoma17. Sotagliflozin: a Dual SGLT1/2 Inhibitor, for Full Range of Heart Failure18. Fezolinetant: the first FDA-approved NK3 receptor antagonist for treating moderate-to-severe vasomotor symptoms associated with menopause19. Gepirone: a selective partial agonist of the 5-HT1A Receptor in the treatment of Depression20. Aducanumab: A Milestone in Alzheimer's Disease Treatment Targeting Amyloid Beta Plaques21. Varoglutamstat (PQ912): Navigating the Frontiers of Alzheimer's Treatment22. Lequembi: Pioneering Hope in Neurodegenerative Disorders - A Breakthrough Drug Shaping the Future of Treatment
